Catalent's (CTLT) proposed acquisition by Novo Nordisk's (NVO) parent Novo Holdings has been approved by the European Commission "unconditionally," the Commission said Thursday.
The Commission said it determined after an investigation that the transaction would not raise competition concerns in the European Economic Area.
Catalent and Novo Holdings said Friday that the transaction is on track to close toward the end of the year.
The all-cash deal, which values Catalent at $16.5 billion, could help boost production of Novo Nordisk's weight-loss drug Wegovy.
Novo Nordisk's shares in the US added 2% in recent Friday trading.
Price: 61.89, Change: -0.23, Percent Change: -0.37
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.